Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study-Reference-Cited by-同舟云学术

Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study

Published:2019 Issue:17 Volume:10 Page:4151-4158
ISSN:1837-9664
Container-title:Journal of Cancer
language:en
Short-container-title:J. Cancer

Author:

Wei Yu-Feng,Huang Wen-Tsung,Liu Tu-Chen,Shieh Jiunn-Min,Chian Chih-Feng,Wu Ming-Fang,Chang Chih-Cheng,Lin Ching-Hsiung,Ko Jen-Chung,Lin Chia-Mo,Hsia Te-Chun

Publisher

Ivyspring International Publisher

Subject

Oncology

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisão Sistemática de Estudos Observacionais sobre o uso de Erlotinibe e Gefitinibe no Tratamento do Câncer de Pulmão de Células Não Pequenas;Revista Brasileira de Cancerologia;2024-08-30

2. Early Changes in Nutritional Status of Elderly Patients with Lung Cancer Undergoing Chemotherapy Are Positively Related with Symptoms of Depression: A Prospective Follow-Up Study;Nutrition and Cancer;2024-07-07

3. Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence;Thoracic Cancer;2023-09-13

4. The impact of comorbidities, neutrophil-to-lymphocyte ratio, and drug toxicities on quality of life in lung cancer patients receiving EGFR-TKI therapy;Journal of the Formosan Medical Association;2023-08

5. The Impact of Comorbidities, Neutrophil-to-lymphocyte Ratio, and Adverse Events on Quality of Life in Lung Cancer Patients Receiving EGFR-TKI Therapy;2022-09-28